Ivana Krajsová1, Petr Arenberger2, Radek Lakomý3, Eugen Kubala4, Ivana Březinová5, Alexandr Poprach3, Marek Šťastný6, Jan Mužík7, Bohuslav Melichar8. 1. Department of Dermato-oncology, University Hospital Prague, and Charles University First Medical Faculty, Prague, Czech Republic Ivana.Krajsova@vfn.cz. 2. Department of Dermatology, University Hospital Vinohrady Prague, and Charles University Third Medical Faculty, Prague, Czech Republic. 3. Department of Comprehensive Cancer Care, Masaryk Oncology Institute Brno, Brno, Czech Republic. 4. Department of Oncology and Radiotherapy, University Hospital Hradec Králové, Hradec Králové, Czech Republic. 5. Department of Oncology, Teaching Hospital Ostrava, Ostrava, Czech Republic. 6. Bristol-Myers Squibb CZ, Prague, Czech Republic. 7. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 8. Department of Oncology, Palacky University Medical School and University Hospital Olomouc, Olomouc, Czech Republic.
Abstract
AIM: Evaluation of efficacy and safety of ipilimumab in patients with advanced, refractory melanoma enrolled into a national ipilimumab Expanded Access Program. PATIENTS AND METHODS: Adult patients with advanced/metastatic refractory melanoma were eligible for study inclusion. Ipilimumab was administered up to a total of four doses. RESULTS: One hundred and ninety-six patients were analyzed. Full ipilimumab induction was administered to 66.8% of patients. Median overall survival (OS) in the entire cohort was 7.5 months. Median OS for patients after four doses of ipilimumab was significantly longer than for patients with fewer doses (12.3 months vs. 2.0 months respectively; p<0.001). Median OS for patients with objective tumor response was 42.3 months. Normal baseline serum lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels, and the number of affected organs correlated with improved OS. CONCLUSION: The number of affected organs and combination of baseline LDH and CRP levels could potentially serve as predictors for both treatment response and OS. Copyright
AIM: Evaluation of efficacy and safety of ipilimumab in patients with advanced, refractory melanoma enrolled into a national ipilimumab Expanded Access Program. PATIENTS AND METHODS: Adult patients with advanced/metastatic refractory melanoma were eligible for study inclusion. Ipilimumab was administered up to a total of four doses. RESULTS: One hundred and ninety-six patients were analyzed. Full ipilimumab induction was administered to 66.8% of patients. Median overall survival (OS) in the entire cohort was 7.5 months. Median OS for patients after four doses of ipilimumab was significantly longer than for patients with fewer doses (12.3 months vs. 2.0 months respectively; p<0.001). Median OS for patients with objective tumor response was 42.3 months. Normal baseline serum lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels, and the number of affected organs correlated with improved OS. CONCLUSION: The number of affected organs and combination of baseline LDH and CRP levels could potentially serve as predictors for both treatment response and OS. Copyright
Authors: Kelcie Witges; Leigh Anne Shafer; Ryan Zarychanski; Ahmed M Abou-Setta; Rasheda Rabbani; Orvie Dingwall; Charles N Bernstein Journal: Drug Saf Date: 2020-12 Impact factor: 5.606
Authors: Hana Studentova; Hana Kalabova; Pavel Koranda; Karin Chytilova; Ladislava Kucerova; Bohuslav Melichar; David Vrana Journal: Oncotarget Date: 2018-04-03
Authors: Wei Fang Dai; Jaclyn M Beca; Ruth Croxford; Wanrudee Isaranawatchai; Ines B Menjak; Teresa M Petrella; Nicole Mittmann; Craig C Earle; Scott Gavura; Timothy P Hanna; Kelvin K W Chan Journal: BMC Cancer Date: 2020-04-15 Impact factor: 4.430